" class="no-js "lang="en-US"> Amy Liao - Medtech Alert
Thursday, September 11, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Amy Liao

Amy Liao

About Amy Liao

Accomplished entrepreneur and executive with a strong background in life sciences enabling customers in the pharmaceutical, biotechnology, diagnostic sectors, and academic research institutions.

Specialties

Global Business Expansion | Strategic Planning & Execution | Mergers & Acquisitions | Customer Needs Analysis
Revenue Growth & Margin Expansion | Technology Adoption & Implementation | Staff Leadership & Training

Related Story

Appointments

 seqWell Appoints Dr Amy Liao to Board of Directors | Pharmtech Focus

seqWell Appoints Dr Amy Liao to Board of Directors

June 15 2022

seqWell, a global provider of genomic library workflow solutions including the plexWell™ next-generation sequencing (NGS) multiplexing technology, […]